URINARY PAIN RELIEF- phenazopyridine hydrochloride tablet Safrel Pharmaceuticals, LLC.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

PHENAZOPYRIDINE HCL Tablet Maximum Strength

Active ingredient (in each tablet)

Phenazopyridine Hydrochloride 99.5 mg

Purpose

Urinary Tract Analgesic

Keep out of reach of children. In case of an overdose, get medical help or contact poison Control Center right away.

Use Relief from urinary pain, burning, urgency and frequency associated with urinary tract infections.

Please read insert for important precautions.

Ask a doctor before use if you have:

kidney disease

allergies to foods, preservatives or dyes

■ had a hypersensitive reaction to Phenazopyridine Hydrochloride

Do not use if you have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency unless approved by your physician.

When using this product

■ stomach upset may occur, taking this product with or after meals may reduce stomach upset

■ your urine will become reddish-orange in color. This is not harmful, but care should be taken to avoid staining clothing or other items.

Stop use and ask a doctor if

- your symptoms last for more than 2 days
- you suspect you are having an adverse reaction to the medication

■ Long-term adminitration of phenazopyridine hydrochloride has induced neoplasia in rats (large instestine) andmice (liver). Although no association between phenazopyridine hydrochloride and human enoplasia has beeen reported, adequate epidemiological studies along these lines have not been conducted.

If pregnant or breast-feeding, ask a health professional before use. A pregnancy test and consultation with a health professional if pregnancy is confirmed is recommended prior to use. **Keep out of reach of children.** In case of an overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

■ This product can interfere with laboratory tests including urine, glucose (sugar), and ketones tests

■ This product may stain contact lenses and other items if handled after touching tablets

■ long term administration of phenazopyridine HCI has induced neoplasia in rats (large intestine) and mice (liver). Although no association between phenazopyridine hydrochloride and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted

Store at room temperature 15°-30°C (59°-86°F) in a dry place and protect from light

■ Adults and children 12 years of age and over: Take 2 tablets 3 times daily with or after meals as needed for up to two days. Take with a full glass of water. Do not use for more than 2 days (12 tablets) without consulting a doctor

■ Children under 12: Do not use wihout consulting a doctor

pregelatinized starch, microcrystalline cellulose, maize (corn) starch, povidone, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, polyethylene glycol

call toll-free 1-845-547-2667

Size and color of tablets may vary.

*This product is not manufactured or distributed by the owner of the registered trademark AZO Urinary Pain Relief®.

Distributed by: Safrel Pharmaceuticals, LLC

Bridgewater, NJ 08807

Compare to the active ingredient in AZO Urinary Pain Relief® Maximum Strength*

MAXIMUM STRENGTH

Urinary Pain Relief

PHENAZOPYRIDINE HYDROCHLORIDE 99.5 mg

Quickly eases urinary pain, burning & urgency

- More active ingredient for maximum relief
- Provides targeted relief for urinary pain

NDC 71309-779-72 - 72 Count



NDC 71309-779-28- 28Count



URINARY PAIN RELI	CC					
phenazopyridine hydrochlori						
Product Information						
Product Type	HUMAN OTC DRUG	ltem Code (Source)		NDC:71309-779		
Route of Administration	ORAL					
Active Ingredient/Active	Moiety					
Ingre		Basis of Strength		Strength		
PHENAZOPYRIDINE HYDROCHLO (PHENAZOPYRIDINE - UNII:K2J09EM		PHENAZ OPYRIDINE HYDROCHLORIDE		99.5 mg		
Inactive Ingredients						
Ingredient Name					Strength	
MAGNESIUM STEARATE (UNII: 70)097M6I30)					
HYDROMELLOSE LINSDECIELED						

HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)

STARCH, CORN (UN	NII: 082321	NY3SI)					
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)							
CELLULOSE, MICR		•					
POVIDONE K30 (UI							
CROSCARMELLOSE SODIUM (UNII: M280L1HH48)							
Product Chara	octeristi	ics					
Color		brown	Score	Score			
Shape		ROUND	Size	Size			
Flavor			Imprint Code	Imprint Code			
Contains							
Packaging							
# Item Code		Package Description		Marketing Start Date	Marketing End Date		
1 NDC:71309-779- 72	72 in 1 B Product	in 1 BOTTLE; Type 0: Not a Combination		08/01/2022			
2 NDC:71309-779- 28				08/01/2022			
Markatica	nf orm	otion					
Marketing							
Marketing Category	Арр	lication Numbe Citat	er or Monograph ion	Marketing Star Date	t Marketing End Date		
unapproved drug other				08/01/2022			

Labeler - Safrel Pharmaceuticals, LLC. (080566287)

Revised: 8/2022

Safrel Pharmaceuticals, LLC.